Psychedelic-Assisted Therapy for Anorexia Nervosa

Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166. https://doi.org/10.1177/0269881119897615

Aleksandrova, L. R., & Phillips, A. G. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences, 42(11). https://doi.org/10.1016/j.tips.2021.08.003

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), 5(33). https://doi.org/10.1176/appi.books.9780890425787

Arcelus, J., Mitchell, A. J., Wales, J., & Nielsen, S. (2011). Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. Archives of General Psychiatry, 68(7), 724–731. https://doi.org/10.1001/archgenpsychiatry.2011.74

Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy‐Profitós, J., & Paradis, G. (2021). Anorexia nervosa and the long‐term risk of mortality in women. World Psychiatry, 20(3), 448–449. https://doi.org/10.1002/wps.20904

Báez-Mendoza, R., & Schultz, W. (2013). The role of the striatum in social behavior. Frontiers in Neuroscience, 7(233). https://doi.org/10.3389/fnins.2013.00233

Bailer, U. F., & Kaye, W. H. (2011). Serotonin: imaging findings in eating disorders. Current Topics in Behavioral Neurosciences, 6(7), 59–79. https://doi.org/10.1007/7854_2010_78

Bailer, U. F., Narendran, R., Frankle, W. G., Himes, M. L., Duvvuri, V., Mathis, C. A., & Kaye, W. H. (2011). Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. International Journal of Eating Disorders, 45(2), 263–271. https://doi.org/10.1002/eat.20937

Balasundaram, P., & Santhanam, P. (2021). Eating Disorders. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK567717/

Bastiaans, J., Grinspoon, L., & B, B. (1983). Mental liberation facilitated by the use of hallucinogenic drugs. Psychedelic Reflections.

Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142(9), 7–19. https://doi.org/10.1016/j.neuropharm.2018.02.018

Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017). Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. Journal of Humanistic Psychology, 57(4), 354–388. https://doi.org/10.1177/0022167817706884

Benfer, N., Spitzer, E. G., & Bardeen, J. R. (2021). Efficacy of Third Wave Cognitive Behavioral Therapies in the Treatment of Posttraumatic Stress: A Meta-analytic Study. Journal of Anxiety Disorders, 33(2), 102360. https://doi.org/10.1016/j.janxdis.2021.102360

Bergen, A. W., Yeager, M., Welch, R. A., Haque, K., Ganjei, J. K., van den Bree, M. B. M., Mazzanti, C., Nardi, I., Fichter, M. M., Halmi, K. A., Kaplan, A. S., Strober, M., Treasure, J., Woodside, D. B., Bulik, C. M., Bacanu, S.-A., Devlin, B., Berrettini, W. H., Goldman, D., & Kaye, W. H. (2005). Association of multiple DRD2 polymorphisms with anorexia nervosa. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 30(9), 1703–1710. https://doi.org/10.1038/sj.npp.1300719

BLUNDELL, J. (1984). Serotonin and appetite. Neuropharmacology, 23(12), 1537–1551. https://doi.org/10.1016/0028-3908(84)90098-4

Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020). Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs, 34(9), 925–946. https://doi.org/10.1007/s40263-020-00748-y

Brewerton, T. D., Wang, J. B., Lafrance, A., Pamplin, C., Mithoefer, M., Yazar-Klosinki, B., Emerson, A., & Doblin, R. (2022). MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. Journal of Psychiatric Research, 149(343), 128–135. https://doi.org/10.1016/j.jpsychires.2022.03.008

Buerger, A., Vloet, T. D., Haber, L., & Geissler, J. M. (2021). Third-wave interventions for eating disorders in adolescence – systematic review with meta-analysis. Borderline Personality Disorder and Emotion Dysregulation, 8(1). https://doi.org/10.1186/s40479-021-00158-6

Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’Diaye, K., Ljuslin, M., Smith, P., Verroust, V., Wyplosz, B., Morgiève, M., & Mallet, L. (2023). Improvement in OCD symptoms associated with serotonergic psychedelics: a retrospective online survey. Scientific Reports, 13(1), 13378. https://doi.org/10.1038/s41598-023-39812-0

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with Psychological Support for treatment-resistant depression: an open-label Feasibility Study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/s2215-0366(16)30065-7

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/nejmoa2032994

Chand, S. P., & Marwaha, R. (2022). Anxiety. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470361/

Chhabra, R., Kremzner, M. E., & Kiliany, B. J. (2005). FDA Policy on Unapproved Drug Products: Past, Present, and Future. Annals of Pharmacotherapy, 39(7-8), 1260–1264. https://doi.org/10.1345/aph.1e569

Cleare, A. J., & Bond, A. J. (2000). Ipsapirone challenge in aggressive men shows an inverse correlation between 5-HT 1A receptor function and aggression. Psychopharmacology, 148(4), 344–349. https://doi.org/10.1007/s002130050061

Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15(21), 39–45. https://doi.org/10.1016/j.jcbs.2019.11.004

Davis, H., & Attia, E. (2017). Pharmacotherapy of eating disorders. Current Opinion in Psychiatry, 30(6), 452–457. https://doi.org/10.1097/yco.0000000000000358

De Gregorio, D., Inserra, A., Enns, J. P., Markopoulos, A., Pileggi, M., El Rahimy, Y., Lopez-Canul, M., Comai, S., & Gobbi, G. (2022). Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. Neuropsychopharmacology, 47(47). https://doi.org/10.1038/s41386-022-01301-9

De Gregorio, D., Pasa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobi, G. (2016). The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacological Research, 113(113), 81–91. https://doi.org/10.1016/j.phrs.2016.08.022

Dechant, E., Boyle, B., & Ross, R. A. (2020). Ketamine in a Patient with Comorbid Anorexia and MDD. Journal of Womens Health and Development, 3(3), 373–375. https://fortuneonline.org/articles/ketamine-in-a-patient-with-comorbid-anorexia-and-mdd.html

Devinsky, O., Morrell, M. J., & Vogt, B. A. (1995). Contributions of anterior cingulate cortex to behaviour. Brain, 118(1), 279–306. https://doi.org/10.1093/brain/118.1.279

Dold, M., Aigner, M., Klabunde, M., Treasure, J., & Kasper, S. (2015). Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. Psychotherapy and Psychosomatics, 84(2), 110–116. https://www.jstor.org/stable/48515954

dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 6(3), 193–213. https://doi.org/10.1177/2045125316638008

Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2021). Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain, 145(2), 441–456. https://doi.org/10.1093/brain/awab406

Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11(1), 1–10. https://doi.org/10.1038/s41398-021-01706-y

DSM-5 DIAGNOSTIC CRITERIA FOR EATING DISORDERS ANOREXIA NERVOSA DIAGNOSTIC CRITERIA. (n.d.). https://www.breathetherapies.co.uk/wp-content/uploads/2019/06/DSM-5-Diagnositic-Criteria-.pdf

Ehrmann, K., Allen, J. J. B., Moreno, F. A., & 34784024. (2022). Psilocybin for the Treatment of Obsessive-Compulsive Disorders. University of Arizona; Springer Science and Business Media Deutschland GmbH. https://experts.arizona.edu/en/publications/psilocybin-for-the-treatment-of-obsessive-compulsive-disorders

Fichter, M. M., Quadflieg, N., Crosby, R. D., & Koch, S. (2017). Long-term outcome of anorexia nervosa: Results from a large clinical longitudinal study. International Journal of Eating Disorders, 50(9), 1018–1030. https://doi.org/10.1002/eat.22736

Foerde, K., Steinglass, J. E., Shohamy, D., & Walsh, B. T. (2015). Neural mechanisms supporting maladaptive food choices in anorexia nervosa. Nature Neuroscience, 18(11), 1571–1573. https://doi.org/10.1038/nn.4136

Frankle, W. G., Lombardo, I., New, A. S., Goodman, M., Talbot, P. S., Huang, Y., Hwang, D.-R., Slifstein, M., Curry, S., Abi-Dargham, A., Laruelle, M., & Siever, L. J. (2005). Brain Serotonin Transporter Distribution in Subjects With Impulsive Aggressivity: A Positron Emission Study With [11C]McN 5652. American Journal of Psychiatry, 162(5), 915–923. https://doi.org/10.1176/appi.ajp.162.5.915

Frostad, S., Danielsen, Y. S., Rekkedal, G. Å., Jevne, C., Dalle Grave, R., Rø, Ø., & Kessler, U. (2018). Implementation of enhanced cognitive behaviour therapy (CBT-E) for adults with anorexia nervosa in an outpatient eating-disorder unit at a public hospital. Journal of Eating Disorders, 6(1). https://doi.org/10.1186/s40337-018-0198-y

Gianni, A. D., De Donatis, D., Valente, S., De Ronchi, D., & Atti, A. R. (2020). Eating disorders: Do PET and SPECT have a role? A systematic review of the literature. Psychiatry Research: Neuroimaging, 300(3), 111065. https://doi.org/10.1016/j.pscychresns.2020.111065

Graybiel, A. M. (2008). Habits, Rituals, and the Evaluative Brain. Annual Review of Neuroscience, 31(1), 359–387. https://doi.org/10.1146/annurev.neuro.29.051605.112851

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2017). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32(1), 49–69. https://doi.org/10.1177/0269881117731279

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5

Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (1973). LSD-Assisted Psychotherapy in Patients with Terminal Cancer. International Pharmacopsychiatry, 8(3), 129–144. https://doi.org/10.1159/000467984

Grzelak, T., Dutkiewicz, A., Paszynska, E., Dmitrzak-Weglarz, M., Slopien, A., & Tyszkiewicz-Nwafor, M. (2017). Neurobiochemical and psychological factors influencing the eating behaviors and attitudes in anorexia nervosa. Journal of Physiology and Biochemistry, 73(2), 297–305. https://doi.org/10.1007/s13105-016-0540-2

Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364–381. https://doi.org/10.1016/j.neuropharm.2011.01.017

Hendricks, P. S. (2018). Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry, 30(4), 331–342. https://doi.org/10.1080/09540261.2018.1474185

Higgins, A. (2018). The Neurobiology of Anorexia Nervosa. In www.intechopen.com. IntechOpen. https://www.intechopen.com/chapters/64858

Holze, F., Avedisian, I., Varghese, N., Eckert, A., & Liechti, M. E. (2021). Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. Frontiers in Pharmacology, 12(12). https://doi.org/10.3389/fphar.2021.711255

Hudspith, M. J., Siddall, P. J., & Munglani, R. (2006, January 1). Chapter 23 - Physiology of pain (H. C. Hemmings & P. M. Hopkins, Eds.). ScienceDirect; Mosby. https://www.sciencedirect.com/science/article/abs/pii/B9780323037075500292

Jardim, A. V., Jardim, D. V., Chaves, B. R., Steglich, M., Ot’alora G., M., Mithoefer, M. C., da Silveira, D. X., Tófoli, L. F., Ribeiro, S., Matthews, R., Doblin, R., & Schenberg, E. E. (2020). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil. Brazilian Journal of Psychiatry, 6(43). https://doi.org/10.1590/1516-4446-2020-0980

Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2016). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135

Kaye, W. H. (1984). Abnormalities in CNS Monoamine Metabolism in Anorexia Nervosa. Archives of General Psychiatry, 41(4), 350. https://doi.org/10.1001/archpsyc.1984.01790150040007

Kaye, W., Gendall, K., & Strober, M. (1998). Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biological Psychiatry, 44(9), 825–838. https://doi.org/10.1016/s0006-3223(98)00195-4

Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G., Ching, T. H. W., Belser, A., & Pittenger, C. (2022). Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon, 8(12), e12135. https://doi.org/10.1016/j.heliyon.2022.e12135

Kerr, K. L., Moseman, S. E., Avery, J. A., Bodurka, J., Zucker, N. L., & Simmons, W. K. (2016). Altered Insula Activity during Visceral Interoception in Weight-Restored Patients with Anorexia Nervosa. Neuropsychopharmacology, 41(2), 521–528. https://doi.org/10.1038/npp.2015.174

Kim, K., Che, T., Panova, O., DiBerto, J. F., Lyu, J., Krumm, B. E., Wacker, D., Robertson, M. J., Seven, A. B., Nichols, D. E., Shoichet, B. K., Skiniotis, G., & Roth, B. L. (2020). Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell, 182(6), 1574-1588.e19. https://doi.org/10.1016/j.cell.2020.08.024

Kingston, K., Szmukler, G., Andrewes, D., Tress, B., & Desmond, P. (1996). Neuropsychological and structural brain changes in anorexia nervosa before and after refeeding. Psychological Medicine, 26(1), 15–28. https://doi.org/10.1017/s0033291700033687

Knatz Peck, S., Shao, S., Murray, S., & Kaye, W. (2022). P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy. Biological Psychiatry, 91(9), S270. https://doi.org/10.1016/j.biopsych.2022.02.686

Kranzler, H. R., & Li, T.-K. (2008). What is addiction? Alcohol Research & Health : The Journal of the National Institute on Alcohol Abuse and Alcoholism, 31(2), 93–95. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860451/

Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology (Oxford, England), 26(7), 994–1002. https://doi.org/10.1177/0269881112439253

Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research. Journal of Psychoactive Drugs, 29(2), 165–183. https://doi.org/10.1080/02791072.1997.10400185

Kurtz, J. S., Patel, N. A., Gendreau, J. L., Yang, C., Brown, N., Bui, N., Picton, B., Harris, M., Hatter, M., Beyer, R., Sahyouni, R., Diaz-Aguilar, L. D., Castellanos, J., Schuster, N., & Abraham, M. E. (2022). The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. Cureus, 14(9), e29167. https://doi.org/10.7759/cureus.29167

Lafrance, A., Loizaga-Velder, A., Fletcher, J., Renelli, M., Files, N., & Tupper, K. W. (2017). Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders. Journal of Psychoactive Drugs, 49(5), 427–435. https://doi.org/10.1080/02791072.2017.1361559

Linardon, J., Fairburn, C. G., Fitzsimmons-Craft, E. E., Wilfley, D. E., & Brennan, L. (2017). The empirical status of the third-wave behaviour therapies for the treatment of eating disorders: A systematic review. Clinical Psychology Review, 58(58), 125–140. https://doi.org/10.1016/j.cpr.2017.10.005

Lochmann, D., & Richardson, T. (2018). Selective Serotonin Reuptake Inhibitors. Antidepressants, 250(172), 135–144. https://doi.org/10.1007/164_2018_172

Marvanova, M., & Gramith, K. (2018). Role of antidepressants in the treatment of adults with anorexia nervosa. Mental Health Clinician, 8(3), 127–137. https://doi.org/10.9740/mhc.2018.05.127

McCulloch, D. E-Wen., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022). Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Frontiers in Pharmacology, 13(44). https://doi.org/10.3389/fphar.2022.841648

Meczekalski, B., Podfigurna-Stopa, A., & Katulski, K. (2013). Long-term consequences of anorexia nervosa. Maturitas, 75(3), 215–220. https://doi.org/10.1016/j.maturitas.2013.04.014

Mesulam, M. (1983). The functional anatomy and hemispheric specialization for directed attention: The role of the parietal lobe and its connectivity. Trends in Neurosciences.

Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236(9). https://doi.org/10.1007/s00213-019-05249-5

Moraczewski, J., Awosika, A. O., & Aedma, K. K. (2023). Tricyclic Antidepressants. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557791/#:~:text=Tricyclic%20antidepressants%20(TCAs)%20constitute%20a

Muratore, A. F., & Attia, E. (2020). Current therapeutic approaches to anorexia nervosa: State of the art. Clinical Therapeutics, 43(1). https://doi.org/10.1016/j.clinthera.2020.11.006

Murphy, R., Straebler, S., Cooper, Z., & Fairburn, C. G. (2010). Cognitive Behavioral Therapy for Eating Disorders. Psychiatric Clinics of North America, 33(3), 611–627. https://doi.org/10.1016/j.psc.2010.04.004

Nagra, J. (2022). Psychedelic Agents as Potential Therapeutics for Obsessive- Compulsive Disorder. https://assets.pubpub.org/e47ukvlp/71644331150766.pdf

Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019). Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature, 569(7754), 116–120. https://doi.org/10.1038/s41586-019-1075-9

Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478

Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2017). Psychedelics as Medicines: An Emerging New Paradigm. Clinical Pharmacology and Therapeutics, 101(2), 209–219. https://doi.org/10.1002/cpt.557

Nunn, K., Frampton, I., Fuglset, T. S., Törzsök-Sonnevend, M., & Lask, B. (2011). Anorexia nervosa and the insula. Medical Hypotheses, 76(3), 353–357. https://doi.org/10.1016/j.mehy.2010.10.038

Olson, D. E. (2022). Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry, 61(3), 127–136. https://doi.org/10.1021/acs.biochem.1c00812

Ona, G., & Bouso, J. C. (2020). Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews, 119(5). https://doi.org/10.1016/j.neubiorev.2020.09.035

Peck, S. K., Shao, S., Gruen, T., Yang, K., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nature Medicine, 29(8), 1–7. https://doi.org/10.1038/s41591-023-02455-9

Raote, I., Bhattacharya, A., & Panicker, M. M. (2007). Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways (A. Chattopadhyay, Ed.). PubMed; CRC Press/Taylor & Francis. https://www.ncbi.nlm.nih.gov/books/NBK1853/#:~:text=5%2DHT2A%20receptor%20agonists

Renelli, M., Fletcher, J., Tupper, K. W., Files, N., Loizaga-Velder, A., & Lafrance, A. (2018). An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 5(34). https://doi.org/10.1007/s40519-018-0619-6

Rienecke, R. (2017). Family-based treatment of eating disorders in adolescents: current insights. Adolescent Health, Medicine and Therapeutics, Volume 8(8), 69–79. https://doi.org/10.2147/ahmt.s115775

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512

Scharner, S., & Stengel, A. (2019). Alterations of brain structure and functions in anorexia nervosa. Clinical Nutrition Experimental, 28(2352-9393). https://doi.org/10.1016/j.yclnex.2019.02.001

Schwartz, T., Trunko, M. E., Feifel, D., Lopez, E., Peterson, D., Frank, G. K. W., & Kaye, W. (2021). A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression. Clinical Case Reports, 9(5). https://doi.org/10.1002/ccr3.3869

Scolnick, B., Zupec-Kania, B., Calabrese, L., Aoki, C., & Hildebrandt, T. (2020). Remission from Chronic Anorexia Nervosa With Ketogenic Diet and Ketamine: Case Report. Frontiers in Psychiatry, 11(763). https://doi.org/10.3389/fpsyt.2020.00763

Shaw, K. A., Turner, J., & Del Mar, C. (2002). Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews, 5(1). https://doi.org/10.1002/14651858.cd003198

Shelley, B. P., & Trimble, M. R. (2004). The insular Lobe of Reil–its Anatamico-Functional, behavioural and Neuropsychiatric attributes in humans–a review. The World Journal of Biological Psychiatry, 5(4), 176–200. https://doi.org/10.1080/15622970410029933

Siegel, S. (1989). Pharmacological Conditioning and Drug Effects. Psychoactive Drugs, 7(2), 115–180. https://doi.org/10.1007/978-1-59259-464-1_3

Smith, M. O. (2016, June 23). Blog | Binge-Purge Anorexia and Bulimia: A DSM | Disorders. Kartiniclinic.com. https://kartiniclinic.com/blog/post/binge-purge-anorexia-vs-bulimia-mental/

Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., Danby, J. L., de Magalhães, F. J. C., Alderton, K. L., Williams, T. M., Blemings, A., Lafrance, A., Nicholls, D. E., Erritzoe, D., Nutt, D. J., & Carhart-Harris, R. L. (2021). Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study.” Frontiers in Psychiatry, 12(735523). https://doi.org/10.3389/fpsyt.2021.735523

Strauss, J. (1987). APA PsycNet. Psycnet.apa.org. https://psycnet.apa.org/record/1987-34989-001

Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzoe, D., Douglass, H., Ketner, H., & Carhart-Harris, R. L. (2021). Psychedelics and health behaviour change. Journal of Psychopharmacology, 36(1), 026988112110085. https://doi.org/10.1177/02698811211008554

Thompson, M. R., Callaghan, P. D., Hunt, G. E., Cornish, J. L., & McGregor, I. S. (2007). A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience, 146(2), 509–514. https://doi.org/10.1016/j.neuroscience.2007.02.032

Tomsovic, M., & Edwards, R. V. (1970). Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Quarterly Journal of Studies on Alcohol, 31(4), 932–949. https://pubmed.ncbi.nlm.nih.gov/5490826/

Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm. Canadian Medical Association Journal, 187(14), 1054–1059. https://doi.org/10.1503/cmaj.141124

van Eeden, A. E., van Hoeken, D., & Hoek, H. W. (2021). Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. Current Opinion in Psychiatry, 34(6), 515–524. https://doi.org/10.1097/yco.0000000000000739

van Elk, M., & Yaden, D. B. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neuroscience & Biobehavioral Reviews, 140(4), 104793. https://doi.org/10.1016/j.neubiorev.2022.104793

Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611–624. https://doi.org/10.1038/s41583-020-0367-2

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 9(17), 3897–3902. https://journals.lww.com/neuroreport/Abstract/1998/12010/Psilocybin_induces_schizophrenia_like_psychosis_in.24.aspx

Wagner, A., Aizenstein, H., Mazurkewicz, L., Fudge, J., Frank, G. K., Putnam, K., Bailer, U. F., Fischer, L., & Kaye, W. H. (2007). Altered Insula Response to Taste Stimuli in Individuals Recovered from Restricting-Type Anorexia Nervosa. Neuropsychopharmacology, 33(3), 513–523. https://doi.org/10.1038/sj.npp.1301443

Wagner, A., Aizenstein, H., Venkatraman, V. K., Fudge, J., May, J. C., Mazurkewicz, L., Frank, G. K., Bailer, U. F., Fischer, L., Nguyen, V., Carter, C., Putnam, K., & Kaye, W. H. (2007). Altered Reward Processing in Women Recovered From Anorexia Nervosa. American Journal of Psychiatry, 164(12), 1842–1849. https://doi.org/10.1176/appi.ajp.2007.07040575

Wichers, M., & Maes, M. (2002). The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. The International Journal of Neuropsychopharmacology, 5(4), 375–388. https://doi.org/10.1017/s1461145702003103

Woerwag-Mehta, S., & Treasure, J. (2008). Causes of anorexia nervosa. Psychiatry, 7(4), 147–151. https://doi.org/10.1016/j.mppsy.2008.02.010

Yaden, D. B., Haidt, J., Hood, R. W., Vago, D. R., & Newberg, A. B. (2017). The Varieties of Self-Transcendent Experience. Review of General Psychology, 21(2), 143–160. https://doi.org/10.1037/gpr0000102

Zafar, R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Shayam Suseelan, Roseman, L., Wall, M., Nutt, D. J., & Erritzoe, D. (2023). Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry, 14(14). https://doi.org/10.3389/fpsyt.2023.1183740

Zipfel, S., Giel, K. E., Bulik, C. M., Hay, P., & Schmidt, U. (2015). Anorexia nervosa: aetiology, assessment, and treatment. The Lancet Psychiatry, 2(12), 1099–1111.

https://doi.org/10.1016/s2215-0366(15)00356-9